Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell-mediated killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin‐2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell‐mediated killing [7].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“We further analyzed genome-wide transcriptional responses of tumors to A2V+aCD40 treatment using gene set enrichment analysis (GSEA) (53).”
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“It is effective in highly mutated MSI CRCs, in which the T cell response has already been elicited (67, 68).”
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687 · cited 1×
“…genes leucine-rich repeat–containing G protein– coupled receptor 5 ( Lgr5 ), lymphoid enhancer binding factor 1 ( Lef1 ), ring finger protein 43 ( Rnf43 ), and Eph receptor B2 ( EphB2 ) (34–36) was decreased but not completely abolished upon loss of expression in desmoplastic CMS4 CRCs (Figure 1C).”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“%) is characterized by low WNT signaling, a high proportion of stromal cells, prominent angiogenesis, and a poor prognosis (4).”
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · cited 11×
“We believe our results have broad implications for the development of novel therapies to treat APC -mutant MSS CRCs, which represent the majority of all CRC cases.”
InfluentialSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890 · cited 2×
“Enrichment was computed using single-sample GSEA (81).”
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491 · cited 1×
“To determine whether fibroblasts accelerate the progression of Prox1 -deficient tumors, we coimplanted AKP or AKPP organ-oids together with fluorescent intestinal fibroblasts isolated from mTmG + mice, in which all cells express the membrane-targeted tdTomato protein (41).”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“5-FU–based adjuvant chemotherapy is the standard of care for CRC and improves patient survival; however, a substantial proportion of the patients either do not respond to this treatment or relapse (2).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“Because CAF-mediated extracellular matrix (ECM) deposition and increased tumor stiffness promote tumor growth (42), we cultured organoids in synthetic hydrogels with a stiffness similar to that of either normal intestine (1.3 kPa) or CRC stroma (2.7 kPa), as described previously (43), in the…”
InfluentialBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 4×
“…Bianchi, 8 Laureline Wetterwald, 1,2 Jaeryung Kim, 1,2 Guillermo Oliver, 9 Mauro Delorenzi, 1,2,3 Michele De Palma, 4 and Tatiana V. Petrova recently been shown to increase sensitivity to PD-1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint blockade in genetic models of CRC (14).”
InfluentialMicroenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 6×
“Although such effects were not sufficient to induce significant cancer cell killing per se, the combination with a CD40 agonist enabled antigen-presenting cell activation and the destruction of cancer cells by CTLs (Figure 7J).”
InfluentialSelf-citationCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672 · cited 4×
“Previous studies have shown that anticancer immunity can be efficiently triggered through the activation of CD40 in desmoplastic pancreatic ductal adenocarcinoma (20, 21).”
InfluentialMarisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507 · cited 1×
“To further study the clinical relevance of these observations, we analyzed the association of PROX1 with clinical outcomes in 444 patients from a prognostically annotated CRC gene expression data set (Gene Expression Omnibus [GEO] GSE39582) (30).”
Designer matrices for intestinal stem cell and organoid culture
Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M. E., Ordóñez-Morán, P., Clevers, H., & Lutolf, M. P. (2016) · Nature · doi:10.1038/nature20168 · Cited by 1,426 · cited 1×
“…matrix (ECM) deposition and increased tumor stiffness promote tumor growth (42), we cultured organoids in synthetic hydrogels with a stiffness similar to that of either normal intestine (1.3 kPa) or CRC stroma (2.7 kPa), as described previously (43), in the presence or absence of fibroblasts.”
InfluentialSelf-citationBatlle, E., Henderson, J. T., Beghtel, H., van den Born, M. M. W., Sancho, E., Huls, G., Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01015-2 · Cited by 1,120
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · cited 1×
“Enrichment in EMT and angiogenesis transcripts is a feature of human desmoplastic CRCs that reflects expansion of the stromal cell compartment (8, 9).”
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060 · cited 2×
“Increased TGF-β signaling or Notch hyperactivation has been shown to promote desmoplasia in CRC models (14, 47, 59), indicating that multiple pathways contribute to stromal expansion in a subset of MSS CRCs.”
Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L. A., Knuechel, R., & Kirchner, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171610498 · Cited by 1,049 · cited 1×
“60), indicating that additional mechanisms control WNT activation in CRC. PROX1 is induced in CRC cells only in response to a high and sustained WNT activation (22).”
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · cited 1×
“In addition to molecular subtypes, a high degree of CD3 + and CD8 + T cell infiltration into the primary tumor is associated with a better prognosis in both MSI and microsatellite stable (MSS) CRCs, where it strongly predicts the time to recurrence, overall survival, and disease-free survival (12).”
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991 · cited 1×
“The role of Tregs in human CRC is controversial: high intratumoral Treg density has been associated with better outcomes (76, 77), whereas other data indicate that Tregs promote protumor Th17 responses and suppress tumor-specific CD8 + T cell activation in patients with CRC (78).”
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944 · cited 1×
“Tregs suppress effector T cells, and a high CD8 + /Treg cell ratio is generally associated with a favorable prognosis in solid cancers (52).”
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926 · cited 1×
“…AP and APP mice by microinjection of tamoxifen Accordingly, mRNA levels of the CAF markers and TGF-β target genes fibroblast activation protein α ( Fap ), periostin ( Postn ), and serpin family E member 1 ( Serpine1 , also known as Pai1 ) (39) were significantly increased (Supplemental Figure 1E).”
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration
Sansom, O. J., Reed, K. R., Hayes, A. J., Ireland, H., Brinkmann, H., Newton, I. P., Batlle, E., Simon-Assmann, P., Clevers, H., Nathke, I. S., et al. (2004) · Genes & Development · doi:10.1101/gad.287404 · Cited by 799 · cited 1×
“Abnormally high WNT signaling is a main driver of cancer cell proliferation, tumor growth, and dedifferentiation in Apc -mutant CRC models (32, 33).”
Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.009 · Cited by 717 · cited 1×
“CD44V6 is a marker of CRC tumor–initiating cells that was previously shown to drive CRC invasion and metastasis (38).”
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640 · cited 2×
“Enrichment in EMT and angiogenesis transcripts is a feature of human desmoplastic CRCs that reflects expansion of the stromal cell compartment (8, 9).”
Petrova, T. V., Mäkinen, T., Mäkelä, T. P., Saarela, J., Virtanen, I., Ferrell, R. E., Finegold, D. N., Kerjaschki, D., Ylä‐Herttuala, S., & Alitalo, K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf470 · Cited by 632
Self-citationRoock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603 · cited 1×
“In addition to APC and TP53 , KRAS is mutated in a significant proportion of CRCs. Constitutive KRAS activation confers an additional growth advantage to APC -mutant cancer cells and promotes resistance to EGFR-targeted therapies in patients with CRC (40).”
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 2×
“In a murine breast cancer model, the simultaneous blockade of VEGFA and ANGPT2 using the bispecific blocking antibody A2V was highly effective in normalizing the tumor vasculature, reprogram-ing the TME, and increasing the efficacy of immune checkpoint blockade (17).”
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563 · cited 1×
“The reversal of tumor vessel abnormality or “vascular normalization” has been shown to increase the penetration of activated immune cells (16).”
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544 · cited 4×
“71, 72 and this study, Supplemental Figure 7B), therefore, we were unable to evaluate whether repeated administration of A2V+aCD40 could suppress tumor growth for more extended time periods.”
Influentialβ-catenin–sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer
Hovanes, K., Li, T. W. H., Munguia, J. E., Truong, T., Milovanovic, T., Lawrence Marsh, J., Holcombe, R. F., & Waterman, M. L. (2001) · Nature Genetics · doi:10.1038/ng0501-53 · Cited by 458 · cited 1×
“…genes leucine-rich repeat–containing G protein– coupled receptor 5 ( Lgr5 ), lymphoid enhancer binding factor 1 ( Lef1 ), ring finger protein 43 ( Rnf43 ), and Eph receptor B2 ( EphB2 ) (34–36) was decreased but not completely abolished upon loss of expression in desmoplastic CMS4 CRCs (Figure 1C).”
Expression of CD44 in Apc and TcfMutant Mice Implies Regulation by the WNT Pathway
Wielenga, V. J. M., Smits, R., Korinek, V., Smit, L., Kielman, M., Fodde, R., Clevers, H., & Pals, S. T. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65297-2 · Cited by 433 · cited 3×
“Interestingly, the WNT-dependent, cancer-specific V6 isoform of the hyaluronan receptor CD44 (37) was strongly upregulated in APP tumors (Supplemental Figure 1, B and D).”
Jackstadt, R., van Hooff, S. R., Leach, J. D., Cortes-Lavaud, X., Lohuis, J. O., Ridgway, R. A., Wouters, V. M., Roper, J., Kendall, T. J., Roxburgh, C. S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.003 · Cited by 433 · cited 2×
“Of note, Notch hyperactivation reduces PROX1 expression (61) and generates desmoplastic, invasive CMS4-like tumors with high TGF-β signaling (59), whereas PROX1 suppresses Notch signaling in colon cancer cells (62).”
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414 · cited 3×
“They also induce tumoricidal macrophages that were shown to control tumors by promoting tumor stroma destruction in the absence of T cell immunity (20, 56, 57).”
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408 · cited 1×
“Of note, the site of tumor implantation may influence tumor growth and its response to therapy (63).”
The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class Switching
Rolink, A., Melchers, F., & Andersson, J. (1996) · Immunity · doi:10.1016/s1074-7613(00)80258-7 · Cited by 405
Roepman, P., Schlicker, A., Tabernero, J., Majewski, I., Tian, S., Moreno, V., Snel, M. H., Chresta, C. M., Rosenberg, R., Nitsche, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28387 · Cited by 346 · cited 2×
“Analysis of clinical responses to adjuvant chemotherapy in patients with stage III CRC revealed a benefit for epithelium-rich CMS2 and CMS3 subgroups, but not for the CMS1 or CMS4 sub-groups (7, 10, 11).”
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346 · cited 1×
“We used B20, a VEGFA-blocking antibody equivalent to bevacizumab (58).”
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338 · cited 1×
“Vascular normalization improves the alignment of ECs and pericytes and vessel functionality and promotes CTL infiltration and activity by increasing the expression of endothelial adhesion receptors for T cell trafficking, thereby reducing hypoxia and relieving high interstitial fluid pressure (75).”
Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity
Johnson, N. C., Dillard, M. E., Baluk, P., McDonald, D. M., Harvey, N. L., Frase, S. L., & Oliver, G. (2008) · Genes & Development · doi:10.1101/gad.1727208 · Cited by 335
Self-citationFrey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333 · cited 1×
“The role of Tregs in human CRC is controversial: high intratumoral Treg density has been associated with better outcomes (76, 77), whereas other data indicate that Tregs promote protumor Th17 responses and suppress tumor-specific CD8 + T cell activation in patients with CRC (78).”
Johansson-Percival, A., He, B., Li, Z.-J., Kjellén, A., Russell, K., Li, J., Larma, I., & Ganss, R. (2017) · Nature Immunology · doi:10.1038/ni.3836 · Cited by 331 · cited 2×
“Angiogenic blockade or the direct delivery of the lymphotoxin β receptor ligand LIGHT to tumor vessels in a genetic model of pancreatic neuroendocrine tumor promoted the formation of HEV-like vessels or de novo formation of TLSs and improved the response to immune therapies (18, 19).”
Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293 · cited 1×
“Moreover, CD40 activation also directly boosts tumor-specific CD8 + T cell immunity and thus may be complementary to immune checkpoint blockade approaches (57, 69).”
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 3×
“Previous studies have shown that anticancer immunity can be efficiently triggered through the activation of CD40 in desmoplastic pancreatic ductal adenocarcinoma (20, 21).”
Long, K. B., Gladney, W. L., Tooker, G. M., Graham, K., Fraietta, J. A., & Beatty, G. L. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1032 · Cited by 275 · cited 3×
“They also induce tumoricidal macrophages that were shown to control tumors by promoting tumor stroma destruction in the absence of T cell immunity (20, 56, 57).”
Lavado, A., Lagutin, O. V., Chow, L. M. L., Baker, S. J., & Oliver, G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000460 · Cited by 238 · cited 1×
“Under physiological conditions, PROX1 specifies cell fate and maintains the expression of lineage-specific genes in lymphatic ECs, cardiomyocytes, hepatocytes, and certain neuronal populations (23–27).”
Self-citationImmune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Engelhard, V. H., Rodriguez, A. B., Mauldin, I. S., Woods, A. N., Peske, J. D., & Slingluff, C. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701269 · Cited by 228 · cited 2×
“These results demonstrate that A2V promoted the generation of tertiary lymphoid structures (TLSs), which are nonencapsulated immune cell aggregates that are associated with productive antitumor immunity and a favorable prognosis in many cancer types, including CRC (55).”
Peske, J. D., Thompson, E. D., Gemta, L., Baylis, R. A., Fu, Y.-X., & Engelhard, V. H. (2015) · Nature Communications · doi:10.1038/ncomms8114 · Cited by 227 · cited 1×
“The presence of TLSs is a generally favorable prognostic factor in human cancers, and they enhance the local antitumor immune response by providing a site for the homing and activation of naive T cells (79).”
Jak3 Is Associated with CD40 and Is Critical for CD40 Induction of Gene Expression in B Cells
Hanissian, S. H., & Geha, R. S. (1997) · Immunity · doi:10.1016/s1074-7613(00)80281-2 · Cited by 205 · cited 1×
“Previous studies documented the important role of CD40 in tumor-associated macrophages, DCs (71), and B cells (74).”
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Petrova, T. V., Nykänen, A., Norrmén, C., Ivanov, K. I., Andersson, L. C., Haglund, C., Puolakkainen, P., Wempe, F., von Melchner, H., Gradwohl, G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.020 · Cited by 192 · cited 4×
“PROX1 is a transcriptional repressor that is overexpressed in a subset of MSS CRCs with high WNT signaling (22).”
InfluentialSelf-citationMembrane-type matrix metalloproteases as diverse effectors of cancer progression
Turunen, S. P., Tatti-Bugaeva, O., & Lehti, K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.002 · Cited by 154 · cited 1×
“MMP14 promotes invasion in several cancers through its ability to degrade collagen and other ECM components (65), thus the increased fibrosis in MMP14-AKP tumors may appear counterintuitive.”
BackgroundFransen, M. F., Sluijter, M., Morreau, H., Arens, R., & Melief, C. J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2888 · Cited by 153 · cited 1×
“Intratumoral-or ECM-targeted delivery of aCD40 antibodies proved highly effective and devoid of systemic toxicity in s.c. sarcoma and melanoma models (72, 73).”
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 150 · cited 1×
“However, the treatment is not effective in patients with microsatellite-stable (MSS) CRC, which accounts for the majority of cases (2, 3).”
Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer
Kim, H.-A., Koo, B.-K., Cho, J.-H., Kim, Y.-Y., Seong, J., Chang, H. J., Oh, Y. M., Stange, D. E., Park, J.-G., Hwang, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61216 · Cited by 139 · cited 1×
“Of note, Notch hyperactivation reduces PROX1 expression (61) and generates desmoplastic, invasive CMS4-like tumors with high TGF-β signaling (59), whereas PROX1 suppresses Notch signaling in colon cancer cells (62).”
Ager, E. I., Kozin, S. V., Kirkpatrick, N. D., Seano, G., Kodack, D. P., Askoxylakis, V., Huang, Y., Goel, S., Snuderl, M., Muzikansky, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv017 · Cited by 136 · cited 2×
“Antibody-mediated MMP14 blockade has shown promising results in limiting the progression of mammary tumor models (66).”
Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines
West, N. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01093 · Cited by 133 · cited 1×
“Furthermore, dermal and intestinal fibroblasts display distinct responses to cytokines (64), thus they may differentially contribute to the tumor response to chemotherapy.”
Prox1 maintains muscle structure and growth in the developing heart
Risebro, C. A., Searles, R. G., Melville, A. A. D., Ehler, E., Jina, N., Shah, S., Pallas, J., Hubank, M., Dillard, M., Harvey, N. L., et al. (2009) · Development · doi:10.1242/dev.030007 · Cited by 130
Self-citationFurman, R. R., Forero, A., Shustov, A. R., & Drachman, J. G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903440946 · Cited by 118 · cited 1×
“Our results show that the antitumor efficacy of aCD40 monotherapy is limited, as observed in other tumor models and in clinical trials (20, 56, 70).”
BackgroundSpatial and phenotypic immune profiling of metastatic colon cancer
Lazarus, J., Maj, T., Smith, J. J., Perusina Lanfranca, M., Rao, A., D’Angelica, M. I., Delrosario, L., Girgis, A., Schukow, C., Shia, J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121932 · Cited by 107 · cited 1×
“Engagement of CD8 + T cells with epithelial cells is strongly associated with a favorable prognosis in CRC (51).”
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., Maughan, T., McDade, S. S., Johnston, P. G., Longley, D. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15657 · Cited by 94 · cited 1×
“…subtype was also identified, with TGF-β pathway activation, epithelial-to-mesenchymal transition (EMT), and poor prognosis, whereas the CMS4 subtype was distributed among all CRIS subtypes, confirming previous observations that the CMS4 transcriptome is dominated by stromal contribution (5–9).”
Haemopedia: An Expression Atlas of Murine Hematopoietic Cells
de Graaf, C. A., Choi, J., Baldwin, T. M., Bolden, J. E., Fairfax, K. A., Robinson, A. J., Biben, C., Morgan, C., Ramsay, K., Ng, A. P., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.007 · Cited by 93 · cited 1×
“Sur-prisingly, using signatures for mouse immune cell populations (54), we found that, together with the expected increase in DC and T cell signatures, A2V+aCD40 treatment also led to enrichment of B cell–associated transcripts, whereas the macrophage desmoplastic microenvironment.”
Timperi, E., Pacella, I., Schinzari, V., Focaccetti, C., Sacco, L., Farelli, F., Caronna, R., Del Bene, G., Longo, F., Ciardi, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1175800 · Cited by 81 · cited 1×
“The role of Tregs in human CRC is controversial: high intratumoral Treg density has been associated with better outcomes (76, 77), whereas other data indicate that Tregs promote protumor Th17 responses and suppress tumor-specific CD8 + T cell activation in patients with CRC (78).”
Wiener, Z., Högström, J., Hyvönen, V., Band, A. M., Kallio, P., Holopainen, T., Dufva, O., Haglund, C. H., Kruuna, O., Oliver, G. C., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.034 · Cited by 80 · cited 3×
“PROX1 is a transcriptional repressor shown previously to directly repress annexin A1 (ANXA1) in Apc -deficient mouse intestinal stem cells (29) and matrix metalloproteinase 14 (MMP14) in human liver, colon, and breast cancer cell lines (48).”
Self-citationPROX1 Promotes Metabolic Adaptation and Fuels Outgrowth of Wnthigh Metastatic Colon Cancer Cells
Ragusa, S., Cheng, J., Ivanov, K. I., Zangger, N., Ceteci, F., Bernier-Latmani, J., Milatos, S., Joseph, J.-M., Tercier, S., Bouzourene, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.041 · Cited by 73 · cited 5×
“The analysis of WNT target genes in AKPP organoids showed partial attenuation of WNT signaling but no induction of differentiation (Figure 3C), consistent with APP tumor phenotypes (see above) and our previous findings in KRAS -mutant human CRC cell lines (28).”
InfluentialSelf-citationAllen, W. L., Dunne, P. D., McDade, S., Scanlon, E., Loughrey, M., Coleman, H. G., McCann, C., McLaughlin, K., Nemeth, Z., Syed, N. A., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00241 · Cited by 71 · cited 2×
“Analysis of clinical responses to adjuvant chemotherapy in patients with stage III CRC revealed a benefit for epithelium-rich CMS2 and CMS3 subgroups, but not for the CMS1 or CMS4 sub-groups (7, 10, 11).”
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69 · cited 1×
“It is effective in highly mutated MSI CRCs, in which the T cell response has already been elicited (67, 68).”
Romano, G., Santi, L., Bianco, M. R., Giuffrè, M. R., Pettinato, M., Bugarin, C., Garanzini, C., Savarese, L., Leoni, S., Cerrito, M. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7895 · Cited by 66 · cited 1×
“Previous studies demonstrated that 5-FU increases TGF-β release and signaling (44).”
Expression and prognostic value of transcription factor PROX1 in colorectal cancer
Skog, M., Bono, P., Lundin, M., Lundin, J., Louhimo, J., Linder, N., Petrova, T. V., Andersson, L. C., Joensuu, H., Alitalo, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.297 · Cited by 64 · cited 1×
“Our clinical outcome analysis differed from the results of a previous histopathological study (31), therefore, we also analyzed tumors classified according to 5 intrinsic subtypes (6) and found that PROX1 expression was significantly higher in the WNT hi CRIS-C, -”
Self-citationSeth, A., Ye, J., Yu, N., Guez, F., Bedford, D. C., Neale, G. A., Cordi, S., Brindle, P. K., Lemaigre, F. P., Kaestner, K. H., et al. (2014) · Development · doi:10.1242/dev.099481 · Cited by 50 · cited 1×
“Under physiological conditions, PROX1 specifies cell fate and maintains the expression of lineage-specific genes in lymphatic ECs, cardiomyocytes, hepatocytes, and certain neuronal populations (23–27).”
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Ishihara, J., Ishihara, A., Potin, L., Hosseinchi, P., Fukunaga, K., Damo, M., Gajewski, T. F., Swartz, M. A., & Hubbell, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0091 · Cited by 45 · cited 2×
“71, 72 and this study, Supplemental Figure 7B), therefore, we were unable to evaluate whether repeated administration of A2V+aCD40 could suppress tumor growth for more extended time periods.”
PROX1 is a transcriptional regulator of MMP14
Gramolelli, S., Cheng, J., Martinez-Corral, I., Vähä-Koskela, M., Elbasani, E., Kaivanto, E., Rantanen, V., Tuohinto, K., Hautaniemi, S., Bower, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27739-w · Cited by 39 · cited 2×
“PROX1 is a transcriptional repressor shown previously to directly repress annexin A1 (ANXA1) in Apc -deficient mouse intestinal stem cells (29) and matrix metalloproteinase 14 (MMP14) in human liver, colon, and breast cancer cell lines (48).”
Self-citationHögström, J., Heino, S., Kallio, P., Lähde, M., Leppänen, V., Balboa, D., Wiener, Z., & Alitalo, K. K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0451 · Cited by 32 · cited 1×
“Of note, Notch hyperactivation reduces PROX1 expression (61) and generates desmoplastic, invasive CMS4-like tumors with high TGF-β signaling (59), whereas PROX1 suppresses Notch signaling in colon cancer cells (62).”
Hutchins, G. G. A., Treanor, D. E., Wright, A. I., Handley, K., Magill, L., Tinkler‐Hundal, E., Southward, K., Seymour, M., Kerr, D. J., Gray, R. G., et al. (2017) · Histopathology · doi:10.1111/his.13326 · Cited by 31 · cited 2×
“Analysis of clinical responses to adjuvant chemotherapy in patients with stage III CRC revealed a benefit for epithelium-rich CMS2 and CMS3 subgroups, but not for the CMS1 or CMS4 subgroups (7, 10, 11).”
Tanaka-Nozaki, M., Onda, M., Tanaka, N., & Kato, S. (2001) · PubMed · Cited by 26
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“Another intriguing study in mouse colorectal cancer models showed that adaptive resistance to chemotherapy (5-FU and cisplatin) is associated with a pronounced stromal response and T-cell exclusion (291).”
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
“In a good example, blockade of VEGF alongside ANGPT2, when combined with CD40 agonistic antibodies, had an anti-angiogenic and immunostimulatory effect resulting in T-cell mediated killing of cancer cells in a colorectal tumor model [336].”
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell-mediated killing [7].”
BackgroundThe roles of tertiary lymphoid structures in chronic diseases
Sato, Y., Silina, K., van den Broek, M., Hirahara, K., & Yanagita, M. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00706-z · Cited by 320
“In a chemotherapy-resistant colorectal cancer model, the combination of antiangiogenic agents with agonistic anti-CD40 antibody induced vascular normalization, TLS development and T cell-mediated tumour control 125 .”
Metadata
- Authors
- Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., Lutolf, M. P., Perentes, J., Corse, E., Bianchi, R., Wetterwald, L., Kim, J., Oliver, G., Delorenzi, M., De Palma, M., & Petrova, T. V.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- University of Zurich (CH)
- F. Hoffmann-La Roche AG (CH)
- Northwestern University (US)
- Corresponding author
- Petrova, Tatiana V.
- ORCID
- Ragusa, Simone
- Prat-Luri, Borja
- González-Loyola, Alejandra
- Nassiri, Sina
- Squadrito, Mario Leonardo
- Guichard, Alan
- Cavin, Sabrina
- Gjorevski, Nikolce
- Barras, David
- Marra, Giancarlo
- Perentes, Jean
- Corse, Emily
- Bianchi, Roberta
- Wetterwald, Laureline
- Kim, Jaeryung
- Oliver, Guillermo
- Delorenzi, Mauro
- De Palma, Michele
- Petrova, Tatiana V.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1199-1216
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269598
- OpenAlex
- W3004730319
- Cited by
- 56
- References
- 82
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Swiss Cancer League (KLS 3406-02-2016, KFS-3759-08-2015)
- MEDIC Foundation (Not available)
- Fondation de lutte contre le cancer (N/A)
- Roche (N/A)
- Swiss Bridge Foundation (N/A)
- N/A (N/A)
- San Salvatore Foundation (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, desmoplasia, chemoresistance, Prox1, APC mutation, Wnt signaling, MMP-14, tumor stroma, angiopoietin-2, CD40 agonist, tumor fibrosis, T cell immunity, tumor angiogenesis
- MeSH terms
- Antineoplastic Agents, Immunological, Prospero-Related Homeobox 1 Protein, Animals, Cell Line, Humans, Immunotherapy, Neoplasms, Experimental, Neovascularization, Pathologic, Colorectal Neoplasms, Homeodomain Proteins, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Tumor Suppressor Proteins, Adenomatous Polyposis Coli Protein, Vascular Endothelial Growth Factor A, Angiopoietin-2, Mice, Matrix Metalloproteinase 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.